• 10x Genomics posted first-quarter revenue of $150.8 million, down 3% year over year; excluding $16.8 million of one-time license and royalty revenue in prior-year quarter, revenue rose 9%.
• Operating loss narrowed to $17 million from $39.3 million year over year, while net loss improved to $13.5 million from $34.4 million.
• Gross margin increased 2 percentage points to 70% due to lower warranty costs and lower inventory write-downs.
• Operating expenses fell 15% to $123.2 million on lower outside legal expenses and personnel expenses.
• Launched Atera platform, with shipments expected in second half of 2026; maintained full-year revenue guidance of $600 million to $625 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 10x Genomics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-032073), on May 07, 2026, and is solely responsible for the information contained therein.